Literature DB >> 21565240

Effect of vesicle size on tissue localization and immunogenicity of liposomal DNA vaccines.

Myrra G Carstens1, Marcel G M Camps, Malou Henriksen-Lacey, Kees Franken, Tom H M Ottenhoff, Yvonne Perrie, Joke A Bouwstra, Ferry Ossendorp, Wim Jiskoot.   

Abstract

The formulation of plasmid DNA (pDNA) in cationic liposomes is a promising strategy to improve the potency of DNA vaccines. In this respect, physicochemical parameters such as liposome size may be important for their efficacy. The aim of the current study was to investigate the effect of vesicle size on the in vivo performance of liposomal pDNA vaccines after subcutaneous vaccination in mice. The tissue distribution of cationic liposomes of two sizes, 500 nm (PDI 0.6) and 140 nm (PDI 0.15), composed of egg PC, DOPE and DOTAP, with encapsulated OVA-encoding pDNA, was studied by using dual radiolabeled pDNA-liposomes. Their potency to elicit cellular and humoral immune responses was investigated upon application in a homologous and heterologous vaccination schedule with 3 week intervals. It was shown that encapsulation of pDNA into cationic lipsomes resulted in deposition at the site of injection, and strongest retention was observed at large vesicle size. The vaccination studies demonstrated a more robust induction of OVA-specific, functional CD8+ T-cells and higher antibody levels upon vaccination with small monodisperse pDNA-liposomes, as compared to large heterodisperse liposomes or naked pDNA. The introduction of a PEG-coating on the small cationic liposomes resulted in enhanced lymphatic drainage, but immune responses were not improved when compared to non-PEGylated liposomes. In conclusion, it was shown that the physicochemical properties of the liposomes are of crucial importance for their performance as pDNA vaccine carrier, and cationic charge and small size are favorable properties for subcutaneous DNA vaccination.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21565240     DOI: 10.1016/j.vaccine.2011.04.081

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  21 in total

Review 1.  Liposomes as vaccine delivery systems: a review of the recent advances.

Authors:  Reto A Schwendener
Journal:  Ther Adv Vaccines       Date:  2014-11

2.  Negatively Charged Carbon Nanohorn Supported Cationic Liposome Nanoparticles: A Novel Delivery Vehicle for Anti-Nicotine Vaccine.

Authors:  Hong Zheng; Yun Hu; Wei Huang; Sabina de Villiers; Paul Pentel; Jianfei Zhang; Harry Dorn; Marion Ehrich; Chenming Zhang
Journal:  J Biomed Nanotechnol       Date:  2015-12       Impact factor: 4.099

Review 3.  mRNA vaccine delivery using lipid nanoparticles.

Authors:  Andreas M Reichmuth; Matthias A Oberli; Ana Jaklenec; Robert Langer; Daniel Blankschtein
Journal:  Ther Deliv       Date:  2016

Review 4.  Liposomal adjuvant development for leishmaniasis vaccines.

Authors:  Anis Askarizadeh; Mahmoud Reza Jaafari; Ali Khamesipour; Ali Badiee
Journal:  Ther Adv Vaccines       Date:  2017-11-15

Review 5.  Modulating the immune system through nanotechnology.

Authors:  Tamara G Dacoba; Ana Olivera; Dolores Torres; José Crecente-Campo; María José Alonso
Journal:  Semin Immunol       Date:  2017-10-09       Impact factor: 11.130

6.  Local Delivery of Ox40l, Cd80, and Cd86 mRNA Kindles Global Anticancer Immunity.

Authors:  Ole Audun Werner Haabeth; Timothy R Blake; Colin J McKinlay; Anders A Tveita; Adrienne Sallets; Robert M Waymouth; Paul A Wender; Ronald Levy
Journal:  Cancer Res       Date:  2019-01-28       Impact factor: 12.701

7.  A novel and efficient nicotine vaccine using nano-lipoplex as a delivery vehicle.

Authors:  Yun Hu; Hong Zheng; Wei Huang; Chenming Zhang
Journal:  Hum Vaccin Immunother       Date:  2013-10-07       Impact factor: 3.452

Review 8.  A case-study investigating the physicochemical characteristics that dictate the function of a liposomal adjuvant.

Authors:  Yvonne Perrie; Elisabeth Kastner; Randip Kaur; Alexander Wilkinson; Andrew J Ingham
Journal:  Hum Vaccin Immunother       Date:  2013-04-12       Impact factor: 3.452

9.  Vault nanocapsules as adjuvants favor cell-mediated over antibody-mediated immune responses following immunization of mice.

Authors:  Upendra K Kar; Janina Jiang; Cheryl I Champion; Sahar Salehi; Minu Srivastava; Sherven Sharma; Shahrooz Rabizadeh; Kayvan Niazi; Valerie Kickhoefer; Leonard H Rome; Kathleen A Kelly
Journal:  PLoS One       Date:  2012-07-11       Impact factor: 3.240

Review 10.  Mimicking Pathogens to Augment the Potency of Liposomal Cancer Vaccines.

Authors:  Maarten K Nijen Twilhaar; Lucas Czentner; Cornelus F van Nostrum; Gert Storm; Joke M M den Haan
Journal:  Pharmaceutics       Date:  2021-06-24       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.